



ORDER SET

Confirmed or Suspected Viral Respiratory Pathogen(s) - Hospital Inpatient - ADULT

Patient: _____ Allergies: _____

Items preceded by a **bullet** (●) are active orders. Items preceded by a **checkbox** (☐) are only to be carried out if checked.

Weight: _____ kg (actual or self-reported)

1. Clinical Resources

- Refer to Firstline app for NS Health COVID and influenza guidelines
- COVID Non-Severe Therapy Pharmacist Consult Service (7 days a week, 0900-1700)
Phone: 1-833-714-2784
- COVID Moderate-Severe Therapy Pharmacist Consult Service (7 days a week, 0800-1600)
Phone: 1-833-519-2442
- For support with clinical decision-making related to COVID management, contact the COVID Consult Physician On-Call. Phone: QEII Locating at 902-473-2220 and ask for the COVID Physician on-call

2. General Measures

- Droplet and contact precautions. Additional precautions (including airborne precautions) as directed by Infection Prevention and Control (IPAC)
- Avoid aerosol generating medical procedures (AGMP)
- Contact IPAC through switchboard during working hours
- If a patient must leave their room, they must wear a surgical mask, if capable

3. Activity

- As tolerated
- Bed rest With Foley catheter
- Prone COVID patient (including those with low oxygen saturation)
- Other: _____

4. Oxygen Saturation

- Target SpO2:
- Equal to or greater than 94%
 - 88 to 92% (pre-existing chronic lung disease)
 - Other: _____

5. Investigations

- Nasopharyngeal swab for COVID, influenza and respiratory syncytial virus (RSV)
- CBC (profile, auto diff), AST, ALT, creatinine, eGFR, CRP daily x 5 days (recommended for moderate to severe COVID patients)
- D-dimer
- Venous blood gas
- Hepatitis C (diagnosis), hepatitis B core antibody, HBsAb, HBsAg, HIV (if receiving Airvo™ or intubated)
- Chest x-ray

Authorized Prescriber's Signature: _____ Reg. No.: _____

Prescriber's Name: _____ Date: _____ Time: _____

Print

YYYY/MON/DD

HH:MM





ORDER SET

Confirmed or Suspected Viral Respiratory Pathogen(s) - Hospital Inpatient - ADULT

Patient: _____ Allergies: _____

Items preceded by a **bullet** (•) are active orders. Items preceded by a **checkbox** (☐) are only to be carried out if checked.

6. Venous Thromboembolism (VTE) Prophylaxis

- Dalteparin 5,000 units subcut daily (weight 40 to 100 kg)
- Dalteparin 2,500 units subcut daily (weight less than 40 kg)
- Dalteparin 7,500 units subcut daily (weight greater than 100 kg)
- Alternate pharmacological prophylaxis. Specify: _____
- Pharmacological prophylaxis not indicated or contraindicated

7. Influenza A or Influenza B Treatment

For confirmed or suspected (i.e., awaiting influenza test result) infection: (select one)

- Oseltamivir 75 mg po/ng bid x 5 days (CrCl greater than 60 mL/min)
- Oseltamivir 30 mg po/ng bid x 5 days (CrCl 31 to 60 mL/min)
- Oseltamivir 30 mg po/ng daily x 5 days (CrCl 10 to 30 mL/min)
- CrCl less than 10 mL/min and renal replacement strategies: _____
(Refer to Firstline app for dosing)
- Discontinue oseltamivir if influenza negative

8. COVID Treatment

Asymptomatic COVID Treatment

- No COVID directed therapies indicated

Non-Severe COVID Treatment

COVID symptoms WITHOUT evidence of lower respiratory disease (all the following must apply):

- No new hypoxemia or desaturation with minimal exertion
- No new significant shortness of breath
- No worsening baseline shortness of breath for those with respiratory disease
- SpO2 equal to or greater than 94% OR no change from baseline

Inhaled Corticosteroid

- Consider for mild respiratory COVID symptoms (e.g., respiratory symptoms including cough) within 14 days of symptom onset
- Budesonide dry powder inhaler 800 mcg bid x 14 days or until symptom recovery
(Do NOT substitute with nebulas, alternative inhaled corticosteroids, or oral/IV steroids)

Antiviral Therapies for Non-Severe COVID

- Prescribed by a Non-Severe COVID Designated Prescriber for high-risk individuals meeting referral criteria (see NS Health Emerging and Re-emerging Infections Hub Treatments and Interventions, COVID-19 Medications, "**Nirmatrelvir/ritonavir (Paxlovid™) and Remdesivir (Veklury®) Referral Criteria For Non-Severe COVID-19**")
- Complete **Report and Support** on-line form to initiate assessment for Paxlovid™ (nirmatrelvir/ritonavir) or Veklury® (remdesivir)

Authorized Prescriber's Signature: _____ Reg. No.: _____

Prescriber's Name: _____ Date: _____ Time: _____
Print YYYYY/MON/DD HH:MM





**ORDER SET
Confirmed or Suspected Viral Respiratory Pathogen(s) - Hospital Inpatient -
ADULT**

Patient: _____ Allergies: _____

Items preceded by a **bullet (•)** are active orders. Items preceded by a **checkbox (☐)** are only to be carried out if checked.

Moderate - Severe COVID Treatment

COVID symptoms with:

- New or worsening baseline hypoxemia **AND/OR**
- Bilateral airspace disease on chest x-ray **AND/OR**
- SpO2 less than or equal to 94% on room air or requiring supplemental oxygen or mechanical ventilation (including extracorporeal membrane oxygenation (ECMO))

Systemic Corticosteroid

- Dexamethasone 6 mg po/ng/IV daily x 10 days or until hospital discharge (whichever is sooner)
 - If pregnant, see Corticosteroid Treatment for Pregnant COVID-19 Patient order set

Respiratory

- Salbutamol 100 mcg MDI 2 puffs q4h with aerochamber
- Salbutamol 100 mcg MDI 2 puffs q1h prn with aerochamber
- Ipratropium 20 mcg MDI 2 puffs q4h prn with aerochamber

Additional Therapies for Moderate-Severe COVID

- Antiviral and/or Interleukin-6 Inhibitor or Janus Kinase (JAK) Inhibitor are prescribed by a COVID Moderate to Severe Designated Prescriber

Antiviral Therapy

- Consider initiation of remdesivir

Interleukin-6 Inhibitor

- Consider initiation of tocilizumab in patient with SpO2 less than or equal to 92% on room air or supplemental oxygen, and systemic inflammation (e.g.: C reactive protein above 75 mg/L) due to COVID.

Janus Kinase (JAK) Inhibitor

- Consider baricitinib initiation in moderate, severe, or critical COVID with evidence of systemic inflammation

9. Respiratory Syncytial Virus (RSV) Treatment

- Antiviral therapy is not routinely used for RSV

Authorized Prescriber's Signature: _____ Reg. No.: _____

Prescriber's Name: _____ Date: _____ Time: _____
Print YYYYY/MON/DD HH:MM

